Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients

Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently not well controlled, despite intensive guideline-based therapy. The unique monoclonal antibody approved for patients with severe allergic asthma is omalizumab: a recombinant humanised murine against IgE an...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of immunopathology and pharmacology Vol. 25; no. 2; p. 475
Main Authors:	Riccio, A M, Dal Negro, R W, Micheletto, C, De Ferrari, L, Folli, C, Chiappori, A, Canonica, G W
Format:	Journal Article
Language:	English
Published:	England 01.04.2012
Subjects:	Adult Anti-Asthmatic Agents - therapeutic use Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Asthma - diagnosis Asthma - drug therapy Asthma - immunology Asthma - pathology Basement Membrane - drug effects Basement Membrane - pathology Biopsy Bronchi - drug effects Bronchi - immunology Bronchi - pathology Eosinophils - drug effects Eosinophils - immunology Female Humans Italy Male Middle Aged Omalizumab Respiratory Hypersensitivity - diagnosis Respiratory Hypersensitivity - drug therapy Respiratory Hypersensitivity - immunology Respiratory Hypersensitivity - pathology Severity of Illness Index Time Factors Treatment Outcome Italy
ISSN:	0394-6320
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!